RNS I New Delhi: Covid-19 deterrent vaccine for children of age more than three years will be available in the country within next six months.
Adar Poonawalla, CEO Serum Institute of India (SII) on Tuesday said, we are planning to launch a vaccine for children aged above three years within the next six months.
Speaking at the 27th CII Partnership Summit 2021 during a virtual conference, Poonawalla said the vaccine, Covovax, is under trial. “At the moment, Covishield is not recommended or approved in people below the age of 18, so Covovax is under trials and has shown excellent data all the way down to the age group of three years,” he added.
Poonawalla pointed out that the vaccine is the Covid-19 shot from the US biotechnology company Novavax, which his company (SII) would produce and distribute locally as Covovax.
He further said that, two other companies have joined us in developing vaccines for children.
Poonawala said that, globally the supply of vaccines has outmatched its demand, and to overcome supply issues, the countries need to prepare some standard rules for clinical trials and manufacturing of the vaccines.
The CII Partnership Summit was organised in association with Department for Promotion of Industry and Internal Trade (DPIIT).
